Rene Em Toes

Rene Em Toes

Auto-generated profile, based on publicly available information

Rene Em Toes

Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2013 in Nature
Verified
Journal Article
Open access
PDF file
TCthe RACI consortium
the RACI consortium
YOYukinori Okada
Yukinori Okada
TCthe GARNET consortium
the GARNET consortium
DWDi Wu
Di Wu
GTGosia Trynka
Gosia Trynka
RPRobert M. Plenge
Robert M. Plenge
A genome-wide association study meta-analysis of more than 100,000 subjects of European and Asian ancestries reveals 42 new risk loci for rheumatoid arthritis, with follow-up studies identifying 98 biological candidate genes that are either already being targeted by drugs or could be in the future. Virtual screening in a genome-wide association study (GWAS) meta-analysis of more than 100,000 subjects of European and Asian ancestries has revealed 42 previously unknown risk loci for rheumatoid arthritis (RA). As a follow-up, the authors developed a new in silico pipeline to identify 98 biological candidate genes at all known RA risk loci. They show that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets to provide insight into disease pathogenesis and guide drug discovery for complex traits such as rheumatoid arthritis (RA)1. Here we performed a genome-wide association study meta-analysis in a total of >100,000 subjects of European and Asian ancestries (29,880 RA cases and 73,758 controls), by evaluating ∼10 million single-nucleotide polymorphisms. We discovered 42 novel RA risk loci at a genome-wide level of significance, bringing the total to 101 (refs 2, 3, 4). We devised an in silico pipeline using established bioinformatics methods based on functional annotation5, cis-acting expression quantitative trait loci6 and pathway analyses7,8,9—as well as novel methods based on genetic overlap with human primary immunodeficiency, haematological cancer somatic mutations and knockout mouse phenotypes—to identify 98 biological candidate genes at these 101 risk loci. We demonstrate that these genes are the targets of approved therapies for RA, and further suggest that drugs approved for other indications may be repurposed for the treatment of RA. Together, this comprehensive genetic study sheds light on fundamental genes, pathways and cell types that contribute to RA pathogenesis, and provides empirical evidence that the genetics of RA can provide important information for drug discovery.

1 June 1998 in Nature
Verified
Journal Article
Closed access
PDF file
SSStephen P. Schoenberger
Stephen P. Schoenberger
RTRene E. M. Toes
Rene E. M. Toes
EVEllen I. H. van der Voort
Ellen I. H. van der Voort
RORienk Offringa
Rienk Offringa
CMCornelis J. M. Melief
Cornelis J. M. Melief

9 May 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BCBIRAC Consortium
BIRAC Consortium
ESEli A Stahl
Eli A Stahl
YCYEAR Consortium
YEAR Consortium
SRSoumya Raychaudhuri
Soumya Raychaudhuri
ERElaine F Remmers
Elaine F Remmers
RPRobert M Plenge
Robert M Plenge

21 December 2006 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JWJun Wang
Jun Wang
AIAndreea Ioan‐Facsinay
Andreea Ioan‐Facsinay
EVEllen I. H. van der Voort
Ellen I. H. van der Voort
THTom W. J. Huizinga
Tom W. J. Huizinga
RTRené E. M. Toes
René E. M. Toes
Foxp3 plays a key role in CD4+CD25+ Treg cell function in mice and represents a specific marker for these cells. Despite the strong association between FOXP3 expression and regulatory function in fresh human T cells, little is known about the dynamics of endogenous FOXP3 expression and its relation to the suppressive function in activated human T cells. Here, we addressed the dynamics of FOXP3 expression during human CD4+ T cell activation by plate‐bound anti‐CD3 Ab as well as the relationship between its expression and regulatory function at the single‐cell level. Our data show that FOXP3 is expressed in a high percentage of activated T cells after in vitro stimulation of human CD4+CD25– cells. FOXP3 expression is strongly associated with hyporesponsiveness of activated T cells, but is not directly correlated with their suppressive capabilities, as we demonstrate that it is also expressed in activated nonsuppressive T cells. However, in this nonsuppressive T cell population, FOXP3 expression is transient, while it is stably expressed in activated T cells that do display suppressive function, and in natural CD4+CD25++ Treg cells. These data indicate that expression of endogenous FOXP3, in humans, is not sufficient to induce regulatory T cell activity or to identify Treg cells.See accompanying commentary http://dx.doi.org/10.1002/eji.200636929

17 September 2001 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
PDF file
RSRoger P.M. Sutmuller
Roger P.M. Sutmuller
LDLeonie M. van Duivenvoorde
Leonie M. van Duivenvoorde
AEAndrea van Elsas
Andrea van Elsas
TSTon N.M. Schumacher
Ton N.M. Schumacher
MWManon E. Wildenberg
Manon E. Wildenberg
CMCornelis J.M. Melief
Cornelis J.M. Melief
Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

1 May 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
UHUlrike Harre
Ulrike Harre
DGDan Georgess
Dan Georgess
HBHolger Bang
Holger Bang
ABAline Bozec
Aline Bozec
RARoland Axmann
Roland Axmann
GSGeorg Schett
Georg Schett
Autoimmunity is complicated by bone loss. In human rheumatoid arthritis (RA), the most severe inflammatory joint disease, autoantibodies against citrullinated proteins are among the strongest risk factors for bone destruction. We therefore hypothesized that these autoantibodies directly influence bone metabolism. Here, we found a strong and specific association between autoantibodies against citrullinated proteins and serum markers for osteoclast-mediated bone resorption in RA patients. Moreover, human osteoclasts expressed enzymes eliciting protein citrullination, and specific N-terminal citrullination of vimentin was induced during osteoclast differentiation. Affinity-purified human autoantibodies against mutated citrullinated vimentin (MCV) not only bound to osteoclast surfaces, but also led to robust induction of osteoclastogenesis and bone-resorptive activity. Adoptive transfer of purified human MCV autoantibodies into mice induced osteopenia and increased osteoclastogenesis. This effect was based on the inducible release of TNF-α from osteoclast precursors and the subsequent increase of osteoclast precursor cell numbers with enhanced expression of activation and growth factor receptors. Our data thus suggest that autoantibody formation in response to citrullinated vimentin directly induces bone loss, providing a link between the adaptive immune system and bone.